Regencell Bioscience Holdings Ltd

NASDAQ RGC

Download Data

Regencell Bioscience Holdings Ltd Current Assets to Total Assets Ratio 3 year CAGR for the year ending June 30, 2023: 6.94%

Regencell Bioscience Holdings Ltd Current Assets to Total Assets Ratio 3 year CAGR is 6.94% for the year ending June 30, 2023, a 331.23% change year over year. The current assets to total assets ratio measures the proportion of a company's current assets in relation to its total assets. It is calculated by dividing current assets by total assets. This ratio indicates the percentage of a company's total assets that are in the form of current assets, such as cash, receivables, and inventory. It provides insights into the company's liquidity and the extent to which its assets are readily convertible to cash in the short term. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Regencell Bioscience Holdings Ltd Current Assets to Total Assets Ratio for the year ending June 30, 2022 was 0.91, a 364.35% change year over year.
  • Regencell Bioscience Holdings Ltd Current Assets to Total Assets Ratio for the year ending June 30, 2021 was 0.20, a -73.89% change year over year.
  • Regencell Bioscience Holdings Ltd Current Assets to Total Assets Ratio for the year ending June 30, 2020 was 0.75, a -24.71% change year over year.
  • Regencell Bioscience Holdings Ltd Current Assets to Total Assets Ratio for the year ending June 30, 2019 was 1.00, a 513.62% change year over year.
NASDAQ: RGC

Regencell Bioscience Holdings Ltd

CEO Mr. Yat-Gai Au
IPO Date July 16, 2021
Location Hong Kong
Headquarters First Commercial Building, Causeway Bay, Hong Kong
Employees 12
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Similar companies

EGRX

Eagle Pharmaceuticals Inc

NA

NA

PAHC

Phibro Animal Health Corporation

NA

NA

PROC

Procaps Group SA

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email